title: Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
abstract: Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and efficacy of etanercept therapy in patients with psoriatic arthritis (PsA) in routine dermatologic practice. We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment.
authors.affiliation: Clinical Partners LLC, Cranston, Rhode Island 02910, USA. riskindoc@aol.com
authors.forename: Ellen H
authors.initials: EH
authors.lastname: Frankel
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Strober
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Crowley
authors.forename: David P
authors.initials: DP
authors.lastname: Fivenson
authors.forename: J Michael
authors.initials: JM
authors.lastname: Woolley
authors.forename: Elaine B
authors.initials: EB
authors.lastname: Yu
authors.forename: Hong A
authors.initials: HA
authors.lastname: Xia
authors.forename: Chiun-Fang
authors.initials: CF
authors.lastname: Chiou
authors.forename: Seth R
authors.initials: SR
authors.lastname: Stevens
mesh_terms: D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D006304:Health Status; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000068800:Etanercept